PI 3-kinase C2α Inhibitors
The chemical class of PI 3-kinase C2α inhibitors comprises a diverse array of compounds designed to modulate the activity of PI 3-kinase C2α, a crucial kinase involved in various cellular processes. Wortmannin, a direct inhibitor, covalently modifies the kinase's active site, impeding its ability to phosphorylate phosphatidylinositol substrates. LY294002 competes with ATP for binding to the kinase, disrupting its catalytic activity and affecting downstream signaling pathways. PI-103, a dual PI 3-kinase and mTOR inhibitor, provides a comprehensive approach to inhibit PI 3-kinase C2α and downstream signaling. AS252424, a potent and selective inhibitor, binds to the ATP-binding site of the kinase, suppressing its activity and offering a valuable tool for understanding the specific functions of PI 3-kinase C2α. IC87114, primarily a PI 3-kinase δ inhibitor, exhibits inhibitory effects on PI 3-kinase C2α, influencing cellular processes.
Compounds like YM201636, TGX-221, CAL-101, and GDC-0941 specifically target PI 3-kinase C2α, disrupting its kinase activity and downstream signaling cascades. ZSTK474, a broad-spectrum PI 3-kinase inhibitor, affects multiple isoforms, including PI 3-kinase C2α, providing a tool to study its functions comprehensively. BYL719, while selective for PI 3-kinase α, exhibits some inhibitory effects on PI 3-kinase C2α, influencing downstream signaling pathways. Additionally, 3-Methyladenine (3-MA) indirectly modulates PI 3-kinase C2α by inhibiting autophagy, a process regulated by this isoform. This indirect modulation offers insights into the interconnected roles of PI 3-kinase C2α in cellular processes beyond its direct catalytic activity. In summary, these PI 3-kinase C2α inhibitors provide a powerful toolkit for researchers to dissect the specific functions of this kinase in various cellular contexts. By targeting its catalytic activity or influencing related cellular processes, these compounds contribute to our understanding of PI 3-kinase C2α's roles and potential implications in diseases where dysregulation of this isoform is implicated.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a direct inhibitor of PI 3-kinase C2α. It covalently modifies the kinase's active site, hindering its ability to phosphorylate phosphatidylinositol substrates. This inhibition disrupts downstream signaling cascades involved in cellular processes such as vesicle trafficking and membrane dynamics. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a selective PI 3-kinase inhibitor that affects both Class I and Class III isoforms. Its inhibition of PI 3-kinase C2α occurs through competitive binding to the ATP-binding site, disrupting the kinase's ability to phosphorylate its substrates and thereby modulating cellular processes dependent on PI 3-kinase activity. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a dual PI 3-kinase and mTOR inhibitor. It acts on PI 3-kinase C2α by blocking its kinase activity and inhibiting downstream signaling pathways. This compound serves as an effective inhibitor to study the role of PI 3-kinase C2α in cellular processes, including vesicle trafficking, membrane dynamics, and autophagy. | ||||||
AS-252424 | 900515-16-4 | sc-202961 sc-202961A | 1 mg 5 mg | $42.00 $158.00 | ||
AS252424 is a potent and selective PI 3-kinase C2α inhibitor. It modulates the kinase's activity by binding to its ATP-binding site, leading to the suppression of downstream signaling pathways. AS252424 represents a valuable tool for investigating the specific functions of PI 3-kinase C2α in cellular processes and potential therapeutic applications. | ||||||
IC-87114 | 371242-69-2 | sc-364509 sc-364509A | 5 mg 50 mg | $140.00 $1060.00 | 1 | |
IC87114 is a selective inhibitor of PI 3-kinase δ, but it also exhibits inhibitory effects on PI 3-kinase C2α. By blocking the kinase activity of PI 3-kinase C2α, IC87114 interferes with cellular processes influenced by this isoform, providing insights into its role in signaling pathways and potential implications in diseases where PI 3-kinase C2α is dysregulated. | ||||||
YM201636 | 371942-69-7 | sc-204193 | 5 mg | $217.00 | 6 | |
YM201636 is an inhibitor of PI 3-kinase C2α, targeting its kinase activity. It acts by binding to the ATP-binding site of the kinase, inhibiting its phosphorylation of phosphatidylinositol substrates. This inhibition leads to the modulation of cellular processes dependent on PI 3-kinase C2α, offering a pharmacological tool for studying its functions and potential therapeutic applications. | ||||||
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
TGX-221 is a selective inhibitor of PI 3-kinase C2α. By binding to the kinase's ATP-binding site, TGX-221 disrupts its catalytic activity, leading to downstream effects on cellular processes regulated by PI 3-kinase C2α. This compound provides a specific means to investigate the isoform's role in signaling pathways and cellular functions. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
CAL-101, also known as Idelalisib, is a selective inhibitor of PI 3-kinase δ but also exhibits inhibitory effects on PI 3-kinase C2α. It modulates PI 3-kinase C2α activity by disrupting downstream signaling pathways. CAL-101 serves as a pharmacological tool to explore the functions of PI 3-kinase C2α and its potential implications in diseases where this isoform is dysregulated. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a pan-PI 3-kinase inhibitor that affects multiple isoforms, including PI 3-kinase C2α. By targeting the ATP-binding site of PI 3-kinase C2α, GDC-0941 inhibits its kinase activity, leading to the modulation of downstream signaling pathways. This compound provides insights into the role of PI 3-kinase C2α in cellular processes and offers potential therapeutic implications. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is a broad-spectrum PI 3-kinase inhibitor that targets multiple isoforms, including PI 3-kinase C2α. Its inhibition of PI 3-kinase C2α occurs by blocking the kinase's ATP-binding site, leading to downstream effects on cellular processes. ZSTK474 serves as a valuable tool for investigating the functions of PI 3-kinase C2α and its potential implications in diseases. | ||||||